Zafgen, Inc. Appoints Matthias Jaffe to Chief Financial Officer and Vice President of Business Development
Cambridge, MA, May 5, 2009 – Zafgen, Inc., a private venture-backed biopharmaceutical
company focused on developing novel obesity therapeutics, today announced the appointment of
Matthias Jaffe to chief financial officer and vice president of business development. Mr. Jaffe
brings to Zafgen extensive finance, acquisition and business development experience.
“I am very pleased to welcome Matthias to his role on our leadership team,” said Thomas
Hughes, Ph.D., president and chief executive officer of Zafgen. “As we advance our corporate
and clinical development strategy, Matthias’ deep financial and business development expertise
will be invaluable.”
Mr. Jaffe brings over ten years of experience in corporate finance and strategic management to
his new role. Prior to joining Zafgen, Mr. Jaffe served as chief financial officer in a number of
private, venture-backed life science organizations, most recently with Alantos Pharmaceuticals.
During his time with Alantos, he successfully led the company through its acquisition by Amgen
for more than $300 million in cash. Previously, Mr. Jaffe was a principal at Earlybird Venture
Capital, based in Munich Germany and worked at the Boston Consulting Group, as a member of
their pharmaceutical practice group. Mr. Jaffe holds a M.S. in molecular biology from the
Massachusetts Institute of Technology, an M.B.A. from INSEAD (Fontainebleau, France) and a
B.S. in chemistry from Universidad Simon Bolivar (Caracas, Venezuela).
“I am very excited to join Zafgen at this important time in the company’s growth,” said Mr.
Jaffe. “The promise of developing new therapeutics to treat the growing obesity epidemic by
targeting and shrinking fat tissue is groundbreaking and presents an extremely exciting
opportunity. I look forward to bringing my leadership and management capabilities to the team
as we seek to develop this novel treatment option.”
About Zafgen, Inc.
Zafgen is the first biopharmaceutical company dedicated to developing novel obesity
therapeutics that directly target and shrink fat tissue to help the body regain and sustain a lean,
healthy state. Adipose tissue (fat) is composed primarily of cells that store unused calories, as
well as an extensive network of blood vessels that support the tissue. The nature of the tissue
and the interplay between fat cells and the supporting blood vessels play a critical and active role
in determining the overall size of the fat tissue, and therefore, an individual’s weight. Zafgen’s
groundbreaking approach targets obesity at its root cause by safely manipulating and shrinking
the blood supply to fat tissue, driving the loss of fat and a return to a more healthy body weight.
Zafgen's leadership and scientific advisors include the leading experts in obesity, metabolic
disorders and medicinal chemistry. Founded in 2005, the company is located in Cambridge,
Massachusetts. For more information, visit www.zafgen.com.